2. Academic Validation
  3. A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033

A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033

  • Expert Opin Ther Pat. 2011 Dec;21(12):1931-6. doi: 10.1517/13543776.2011.636738.
Peter Norman 1
Affiliations

Affiliation

PMID: 22082220 DOI: 10.1517/13543776.2011.636738
Abstract

This application claims salts and crystalline forms of a previously disclosed DP2 receptor antagonist (2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxy-phenyl]acetic acid (1)). It also claims compositions containing the free acid and its salts, especially the sodium salt and their use in the treatment of inflammatory and respiratory diseases, especially asthma. Notably, the application presents Phase I clinical data on compound (1).

Figures
Products